Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.52 |
| ▸ | BCL2 | P10415 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376536 | 0.88 | BCL2L1 (0.42) | BCL2L1BCL2MAPTLMNA | |
| SCHEMBL376986 | 0.84 | BCL2L1 (0.55) | BCL2L1BCL2 | |
| SCHEMBL13503904 | 0.83 | BCL2L1 (0.45) | BCL2L1BCL2MAPTLMNAALDH1A1 | |
| SCHEMBL376416 | 0.83 | BCL2L1 (0.45) | BCL2L1BCL2MAPTLMNAALDH1A1 | |
| SCHEMBL376731 | 0.80 | BCL2L1 (0.52) | BCL2L1BCL2MAPTLMNAALDH1A1 | |
| SCHEMBL376622 | 0.77 | BCL2L1 (0.88) | BCL2L1BCL2 | |
| SCHEMBL376604 | 0.76 | BCL2L1 (0.46) | BCL2L1BCL2MAPTLMNAALDH1A1 | |
| SCHEMBL3589187 | 0.74 | BCL2L1 (0.50) | BCL2L1BCL2 | |
| SCHEMBL3594991 | 0.73 | BCL2 (0.59) | BCL2L1BCL2 | |
| SCHEMBL376471 | 0.72 | BCL2L1 (0.55) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | BCL2L1 18/4885BCL2 2/4885MAPT 4433/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | BCL2L1 18/4885BCL2 2/4885MAPT 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.